Proton pump inhibitors in rheumatic diseases: clinical practice, drug interactions, bone fractures and risk of infections
Patients affected by acute coronary syndrome (ACS) or by chronic inflammatory musculoskeletal and connective tissue diseases (i.e. systemic sclerosis), often need antiaggregant therapy (ASA or Clopidogrel). The concomitant use of proton pump inhibitors (PPIs) is suggested to reduce the risk of haemo...
Saved in:
Main Authors: | E. Gremese (Author), A. Zoli (Author), A. Laria (Author), G.F. Ferraccioli (Author) |
---|---|
Format: | Book |
Published: |
PAGEPress Publications,
2011-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Proton pump inhibitors in pediatric practice
by: Anna A. Shilova, et al.
Published: (2023) -
The Effect of Proton Pump Inhibitors on Fracture Formation and Reflection on Care
by: Seda Akutay, et al.
Published: (2021) -
RENAL SAFETY OF PROTON PUMP INHIBITORS
by: A. I. Dyadyk, et al.
Published: (2017) -
The Association Between Prolonged Proton Pump Inhibitors Use and Bone Mineral Density
by: Fattahi MR, et al.
Published: (2019) -
Prevalence of proton pump inhibitors drug interactions in community pharmacy: a network analysis approach.
by: Lorena Maria Lima de Araujo, et al.
Published: (2023)